204 related articles for article (PubMed ID: 29506363)
1. [Varicella vaccination: scientific reasons for a different strategic approach].
Donzelli A; Demicheli V
Epidemiol Prev; 2018; 42(1):65-70. PubMed ID: 29506363
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
[TBL] [Abstract][Full Text] [Related]
4. Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.
van Lier A; Lugnér A; Opstelten W; Jochemsen P; Wallinga J; Schellevis F; Sanders E; de Melker H; van Boven M
EBioMedicine; 2015 Oct; 2(10):1494-9. PubMed ID: 26629544
[TBL] [Abstract][Full Text] [Related]
5. Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data.
Goldman GS; King PG
Hum Exp Toxicol; 2014 Aug; 33(8):886-93. PubMed ID: 24275643
[TBL] [Abstract][Full Text] [Related]
6. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.
Horn J; Karch A; Damm O; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Hengel H; Greiner W; Mikolajczyk RT
Hum Vaccin Immunother; 2016 Jul; 12(7):1766-76. PubMed ID: 26835890
[TBL] [Abstract][Full Text] [Related]
7. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
Bilcke J; van Hoek AJ; Beutels P
Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
[TBL] [Abstract][Full Text] [Related]
8. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
[TBL] [Abstract][Full Text] [Related]
9. [Immunization of adults against varicella and herpes zoster].
Hanslik T; Blanchon T; Alvarez FP
Rev Med Interne; 2007 Mar; 28(3):166-72. PubMed ID: 17270316
[TBL] [Abstract][Full Text] [Related]
10. Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs.
Gabutti G; Franchi M; Maniscalco L; Stefanati A
Minerva Pediatr; 2016 Jun; 68(3):213-25. PubMed ID: 27125440
[TBL] [Abstract][Full Text] [Related]
11. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
[TBL] [Abstract][Full Text] [Related]
12. Early impact of universal varicella vaccination on childhood varicella and herpes zoster hospitalizations in Brazil.
Scotta MC; Paternina-de la Ossa R; Lumertz MS; Jones MH; Mattiello R; Pinto LA
Vaccine; 2018 Jan; 36(2):280-284. PubMed ID: 29198917
[TBL] [Abstract][Full Text] [Related]
13. Universal varicella vaccination: efficacy trends and effect on herpes zoster.
Goldman GS
Int J Toxicol; 2005; 24(4):205-13. PubMed ID: 16126614
[TBL] [Abstract][Full Text] [Related]
14. What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model.
Rafferty ERS; McDonald W; Osgood ND; Doroshenko A; Farag M
Value Health; 2021 Jan; 24(1):50-60. PubMed ID: 33431153
[TBL] [Abstract][Full Text] [Related]
15. Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015.
Choi JK; Park SH; Park S; Choi SM; Kim SH; Lee DG; Yoo JH; Choi JH; Kang JH
Hum Vaccin Immunother; 2019; 15(11):2554-2560. PubMed ID: 31008679
[No Abstract] [Full Text] [Related]
16. The cost-effectiveness of varicella vaccination in Canada.
Brisson M; Edmunds WJ
Vaccine; 2002 Jan; 20(7-8):1113-25. PubMed ID: 11803072
[TBL] [Abstract][Full Text] [Related]
17. [Immunization against varicella and zoster].
Floret D
Bull Acad Natl Med; 2007 Jun; 191(6):1051-64; discussion 1064-7. PubMed ID: 18402164
[TBL] [Abstract][Full Text] [Related]
18. The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013.
Hobbelen PH; Stowe J; Amirthalingam G; Miller L; van Hoek AJ
J Infect; 2016 Sep; 73(3):241-53. PubMed ID: 27283754
[TBL] [Abstract][Full Text] [Related]
19. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
Ouwens MJ; Littlewood KJ; Sauboin C; Téhard B; Denis F; Boëlle PY; Alain S
Clin Ther; 2015 Apr; 37(4):816-829.e10. PubMed ID: 25726457
[TBL] [Abstract][Full Text] [Related]
20. Modeling and predicting the long-term effects of various strategies and objectives of varicella-zoster vaccination campaigns.
Riche B; Bricout H; Kürzinger ML; Roche S; Iwaz J; Etard JF; Ecochard R
Expert Rev Vaccines; 2016 Jul; 15(7):927-36. PubMed ID: 27148763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
